ArticleChina CDC weekly2026
National and Provincial Lifetime Risk of Chronic Respiratory Disease - China, 2023.
Article in China CDC weekly, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Chronic respiratory disease (CRD) ranks among the leading causes of morbidity and mortality in China, representing a major public health challenge. Despite this substantial disease burden, the lifetime risk (LTR) of developing CRD in the Chinese population remains poorly characterized. This study systematically estimates the LTR of CRD at both the national level and across all 31 provincial-level administrative divisions (PLADs) in China from 1990 to 2023. Methods: We estimated CRD-related LTRs across China and its 31 PLADs by age, sex, and year, incorporating CRD incidence hazard, CRD-deleted mortality, and CRD-free survival probability derived from incidence, prevalence, and mortality rates. All data were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023. Results: In 2023, the overall LTR of CRD reached 61.30% [95% uncertainty interval ( Conclusion: The LTR of CRD in China has risen substantially since 1990, with marked regional heterogeneity. These geographic disparities underscore the need for precision public health interventions and region-specific resource allocation to effectively curb the rising trajectory of CRD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.